MX368485B - Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol. - Google Patents
Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol.Info
- Publication number
- MX368485B MX368485B MX2015017356A MX2015017356A MX368485B MX 368485 B MX368485 B MX 368485B MX 2015017356 A MX2015017356 A MX 2015017356A MX 2015017356 A MX2015017356 A MX 2015017356A MX 368485 B MX368485 B MX 368485B
- Authority
- MX
- Mexico
- Prior art keywords
- amylin
- polyethyleneglycol
- mimetic compounds
- agglomerating bioconjugates
- bioconjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
Abstract
La presente invención se refiere en general a nuevos bioconjugados no aglomerantes de los compuestos mimétricos de amilina con polietilen glicol, y a su uso principalmente en el tratamiento de las enfermedades asociadas con la deposición o acumulación del amiloide extracelular que contribuye a la disfunción o insufiencia de los órganos sistémicos tales como el páncreas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRBR102013017626-5A BR102013017626A2 (pt) | 2013-06-14 | 2013-06-14 | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
PCT/BR2014/000199 WO2014197961A1 (en) | 2013-06-14 | 2014-06-13 | Non-agglomerating bioconjugates of amylin-mimetic compounds and polyethyleneglycol |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015017356A MX2015017356A (es) | 2016-12-20 |
MX368485B true MX368485B (es) | 2019-10-04 |
Family
ID=52021510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015017356A MX368485B (es) | 2013-06-14 | 2014-06-13 | Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20160331811A1 (es) |
EP (1) | EP3007721B1 (es) |
JP (1) | JP2016526533A (es) |
CN (1) | CN105658234A (es) |
AU (1) | AU2014280869B2 (es) |
BR (1) | BR102013017626A2 (es) |
CA (1) | CA2915104A1 (es) |
ES (1) | ES2720274T3 (es) |
MX (1) | MX368485B (es) |
PL (1) | PL3007721T3 (es) |
PT (1) | PT3007721T (es) |
TR (1) | TR201906773T4 (es) |
WO (1) | WO2014197961A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
PT3498006T (pt) * | 2016-08-12 | 2022-06-28 | Ericsson Telefon Ab L M | Seleção de uma portadora num sistema de funcionamento com múltiplas portadoras |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
US7101853B2 (en) * | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
US20030130177A1 (en) * | 2002-01-08 | 2003-07-10 | Kolterman Orville G. | Use of amylin agonists to modulate triglycerides |
JP2006506386A (ja) * | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ, インコーポレイテッド | 糖尿病の処置 |
US20050143303A1 (en) * | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
DE602005021858D1 (de) * | 2004-02-11 | 2010-07-29 | Amylin Pharmaceuticals Inc | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
EP1871403B1 (en) * | 2005-03-31 | 2010-09-08 | Amylin Pharmaceuticals, Inc. | Compositions and methods for the control, prevention and treatment of eating disorders |
WO2006108052A2 (en) * | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
JP2008536881A (ja) * | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Glp−1分子と制吐剤との医薬製剤 |
WO2007104789A2 (en) * | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
EP2102355B1 (en) * | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
EP2036539A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
CN102036687A (zh) * | 2008-05-16 | 2011-04-27 | 尼克塔治疗公司 | 胆碱酯酶部分与聚合物的共轭物 |
CN103641907A (zh) * | 2008-06-17 | 2014-03-19 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共激动剂 |
US8680263B2 (en) * | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
BRPI1003424A2 (pt) * | 2010-09-08 | 2013-01-08 | Univ Rio De Janeiro | sistema polimÉtrico de confinamento de amilina humana e anÁlogos agonistas, processo e uso; processo de avaliaÇço funcional de amilina liberada |
KR20230148396A (ko) * | 2010-11-12 | 2023-10-24 | 넥타르 테라퓨틱스 | Il-2 부분 및 중합체의 접합체 |
US20140221282A1 (en) * | 2011-05-25 | 2014-08-07 | Astrazeneca Pharmaceuticals Lp | Long duration dual hormone conjugates |
JP6040464B2 (ja) * | 2011-07-08 | 2016-12-07 | アエゲリオン・ファーマシューティカルズ・インコーポレイテッドAegerion Pharmaceuticals, Inc. | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
US20140249076A1 (en) * | 2011-10-18 | 2014-09-04 | Astrazeneca Pharmaceuticals Lp | Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties |
WO2014152820A1 (en) * | 2013-03-14 | 2014-09-25 | Vdopia Inc. | Systems and methods for layering content |
-
2013
- 2013-06-14 BR BRBR102013017626-5A patent/BR102013017626A2/pt not_active Application Discontinuation
-
2014
- 2014-06-13 ES ES14810520T patent/ES2720274T3/es active Active
- 2014-06-13 US US14/898,237 patent/US20160331811A1/en not_active Abandoned
- 2014-06-13 TR TR2019/06773T patent/TR201906773T4/tr unknown
- 2014-06-13 WO PCT/BR2014/000199 patent/WO2014197961A1/en active Application Filing
- 2014-06-13 PT PT14810520T patent/PT3007721T/pt unknown
- 2014-06-13 CA CA2915104A patent/CA2915104A1/en not_active Abandoned
- 2014-06-13 EP EP14810520.8A patent/EP3007721B1/en active Active
- 2014-06-13 JP JP2016518806A patent/JP2016526533A/ja active Pending
- 2014-06-13 MX MX2015017356A patent/MX368485B/es active IP Right Grant
- 2014-06-13 AU AU2014280869A patent/AU2014280869B2/en not_active Ceased
- 2014-06-13 CN CN201480033501.8A patent/CN105658234A/zh active Pending
- 2014-06-13 PL PL14810520T patent/PL3007721T3/pl unknown
-
2015
- 2015-12-14 US US14/968,033 patent/US20160184401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR102013017626A2 (pt) | 2015-02-10 |
US20160184401A1 (en) | 2016-06-30 |
TR201906773T4 (tr) | 2019-05-21 |
WO2014197961A9 (en) | 2016-01-28 |
CN105658234A (zh) | 2016-06-08 |
AU2014280869B2 (en) | 2017-11-02 |
JP2016526533A (ja) | 2016-09-05 |
EP3007721A4 (en) | 2016-12-07 |
PL3007721T3 (pl) | 2019-09-30 |
WO2014197961A1 (en) | 2014-12-18 |
EP3007721B1 (en) | 2019-02-27 |
EP3007721A1 (en) | 2016-04-20 |
AU2014280869A1 (en) | 2016-01-07 |
US20160331811A1 (en) | 2016-11-17 |
CA2915104A1 (en) | 2014-12-18 |
PT3007721T (pt) | 2019-05-13 |
MX2015017356A (es) | 2016-12-20 |
ES2720274T3 (es) | 2019-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018013141A (es) | Neurotoxinas quimericas. | |
MX2017007392A (es) | Tratamiento de convulsiones con fosfatasa alcalina recombinante. | |
NZ730865A (en) | Peptides having anti-inflammatory properties | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
EA201790378A1 (ru) | Заключенное в липосому аффинное лекарственное средство | |
MX2015017532A (es) | Métodos para modular la actividad del regulador de transmembrana de fibrosis quística. | |
IN2014DN09098A (es) | ||
PH12016501702B1 (en) | Pyrazole amide derivative | |
MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
MX2019004500A (es) | Terapia de combinación para la inhibición de componente de complemeto (c3). | |
MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
IN2014DN05885A (es) | ||
MX2022014634A (es) | Metodos para la administracion linfatica de agentes activos. | |
UY34616A (es) | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. | |
EA201890212A1 (ru) | Новое применение сульфата декстрана | |
NZ730092A (en) | Use of cysteamine in treating infections caused by yeasts/moulds | |
ECSP16061208A (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
MX2016000448A (es) | Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido. | |
CL2018002638A1 (es) | Ambrisentan para uso en el tratamiento de insuficiencia renal aguda | |
MX2020003049A (es) | Semaglutida en la terapia medica. | |
MX2015017356A (es) | Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol. | |
ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 | |
NZ711523A (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
MX2018007236A (es) | Bioconjugados no aglomerantes de amilina y compuestos mimeticos de amilina, composiciones que comprenden los mismos, y fabricacion y uso de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |